Utrophin therapy for Duchenne muscular dystrophy?

Roxanne Nelson. Lancet Neurol. 2004 Nov.

. 2004 Nov;3(11):637.

doi: 10.1016/s1474-4422(04)00891-9.

No abstract available

Similar articles

The role of utrophin in the potential therapy of Duchenne muscular dystrophy.
Perkins KJ, Davies KE. Perkins KJ, et al. Neuromuscul Disord. 2002 Oct;12 Suppl 1:S78-89. doi: 10.1016/s0960-8966(02)00087-1. Neuromuscul Disord. 2002. PMID: 12206801 Review.
Progress in gene therapy for Duchenne muscular dystrophy.
Clemens PR, Duncan FJ. Clemens PR, et al. Curr Neurol Neurosci Rep. 2001 Jan;1(1):89-96. doi: 10.1007/s11910-001-0080-0. Curr Neurol Neurosci Rep. 2001. PMID: 11898504 Review.
[Future treatment modalities in Duchenne muscular dystrophy].
Oron A, Shuper A, Shohat M. Oron A, et al. Harefuah. 1998 Apr 1;134(7):557-60. Harefuah. 1998. PMID: 10909603 Review. Hebrew. No abstract available.
An attempt of gene therapy in Duchenne muscular dystrophy: overexpression of utrophin in transgenic mdx mice.
Gillis JM. Gillis JM. Acta Neurol Belg. 2000 Sep;100(3):146-50. Acta Neurol Belg. 2000. PMID: 11098286 Review.
Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
Ebihara S, Guibinga GH, Gilbert R, Nalbantoglu J, Massie B, Karpati G, Petrof BJ. Ebihara S, et al. Physiol Genomics. 2000 Sep 8;3(3):133-44. doi: 10.1152/physiolgenomics.2000.3.3.133. Physiol Genomics. 2000. PMID: 11015608

Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.
Aljamali MN, Margaritis P, Schlachterman A, Tai SJ, Roy E, Bunte R, Camire RM, High KA. Aljamali MN, et al. J Clin Invest. 2008 May;118(5):1825-34. doi: 10.1172/JCI32878. J Clin Invest. 2008. PMID: 18398505 Free PMC article.